ArticleOncology letters2025
Analysis of the efficacy and prognostic factors of gemcitabine combined with oxaliplatin in non-Hodgkin lymphoma.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extranodal nasal-orbital communicating lesions NK/T cell lymphoma with ocular symptoms as the initial manifestation misdiagnosed as sinusitis and orbital cellulitis: a case report and literature review.Frontiers in oncology · 2026Article
- Impact of Nutritional Status on Survival and Development of Hodgkin's Lymphoma: A Scoping Review.Nutrients · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-Hodgkin lymphoma (NHL), a heterogeneous malignancy accounting for ~90% of lymphomas, often requires chemotherapy as the primary treatment for patients unsuitable for stem cell transplantation. This study aimed to analyze the therapeutic effects of gemcitabine combined with oxaliplatin on NHL and examine the prognostic factors affecting patients with NHL. A total of 106 patients with NHL were retrospectively selected and divided into a control group (CG; n=50 received oxaliplatin treatment) and an observation group (OG; n=56 received oxaliplatin combined with gemcitabine treatment) based on the differences in treatment measures. Clinical data, therapeutic efficacy, adverse reactions, improvement in B symptoms, post-treatment levels of lactate dehydrogenase (LDH) and TGF-β1 and post-treatment Karnofsky Performance Status (KPS) scores were collected from patients in both groups. Prognostic factors for NHL were analyzed based on the results of a 2-year follow-up. In the OG, the complete remission rate (CRR) was 73.21% and the disease control rate (DCR) was 91.07%, whereas in the CG, the CRR was 52.00% and the DCR was 80.00%, demonstrating a significant intergroup difference (P<0.05). The OG had an overall survival (OS) of 13.6 months and a progression-free survival (PFS) of 8.9 months, and the CG had an OS of 11.3 months and a PFS of 6.1 months. After chemotherapy, the serum LDH and TGF-β1 levels in the OG were significantly lower compared with those in the CG, and the KPS scores were higher compared with those in the CG (all P<0.05). Multivariate logistic regression analysis indicated that the Ann Arbor stage and the International Prognostic Index score for lymphoma were independent prognostic risk factors for patients with NHL (both P<0.05). The combination therapy of gemcitabine and oxaliplatin was demonstrated to be safe for patients with NHL. This combination treatment demonstrated notable overall efficacy and improved functional improvement compared with oxaliplatin monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.